EQS-News: Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
|
EQS-News: Pentixapharm Holding AG
/ Key word(s): Conference/Scientific publication
Berlin, Germany, April 25, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, will present new pre-clinical data on its novel antibody GT-008 at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago. The presentation highlights GT-008’s unique glycan-dependent binding mechanism, a key advancement for immunotherapy and radioconjugate development. GT-008 is a first-in-class, glycan-dependent monoclonal antibody targeting CD24, a surface protein implicated in tumor progression. By recognizing a tumor-associated O-glycoform of CD24—limited in healthy tissue—the antibody shows high affinity and specificity for cancer cells, while binding to CD24-expressing healthy cells is strongly reduced. This lowers the potential for on-target/off-tumor activity, overcoming key limitations of conventional CD24-targeting antibodies and other binding modalities. GT-008 retains strong binding and internalization in a range of solid tumors, including endometrial, breast, ovarian, and squamous cell carcinoma of the skin. Its format enables flexible payload integration—ranging from cytotoxics to radiotherapeutics—supporting diverse therapeutic modalities. An in vitro and in vivo proof-of-concept study using a radiolabeled version is currently underway—laying the groundwork for what could become the first radioconjugated antibody in Pentixapharm’s development pipeline. Presentation Details:
The poster can be found here: Link
About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based, first-in-class radiopharmaceuticals with strong differentiation and commercialization potential across high-need diagnostic and therapeutic areas. Its pipeline comprises CXCR4-targeted compounds in clinical development and a portfolio of early-stage radionuclide-antibody conjugates, aimed at treating hematologic malignancies, solid tumors, and diseases of the cardiovascular, endocrine, and immune systems.
For more information, please contact: Pentixapharm Holding AG
25.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | info@pentixapharm.com |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2124644 |
| End of News | EQS News Service |
|
|
2124644 25.04.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 0,07 | 0,06 | 0,05 | 1,77 | 0,12 | 0,00 | |
| EBITDA1,2 | 0,00 | -1,85 | -4,07 | -5,89 | -10,62 | 2,07 | 0,00 | |
| EBITDA-Margin3 | 0,00 | -2.642,86 | -6.783,33 | -11.780,00 | -600,00 | 1.725,00 | 0,00 | |
| EBIT1,4 | 0,00 | -1,92 | -4,18 | -6,00 | -10,76 | -16,97 | 0,00 | |
| EBIT-Margin5 | 0,00 | -2.742,86 | -6.966,67 | -12.000,00 | -607,91 | -14.141,67 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | -1,92 | -4,18 | -1,96 | -7,64 | -12,84 | -18,00 | |
| Net-Margin6 | 0,00 | -2.742,86 | -6.966,67 | -3.920,00 | -431,64 | -10.700,00 | 0,00 | |
| Cashflow1,7 | 0,00 | -1,85 | -2,49 | -2,20 | 2,13 | -4,33 | 0,00 | |
| Earnings per share8 | 0,00 | -0,08 | -0,17 | -0,08 | -0,30 | -0,52 | -0,73 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Pentixapharm Holding | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40AEG | DE000A40AEG0 | AG | 37,09 Mio € | 03.10.2024 | Kaufen | 8FXFRW2H+CF |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -1,00 | 0,00 | 0,00 | -1,66 | 1,01 | -8,57 | 314,36 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 27.05.2025 | 08.05.2025 | 06.08.2025 | 12.11.2025 | 15.04.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -7,60% | -32,22% | -49,29% | -50,79% | -70,67% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
